|Table of Contents|

Expression of FABP4 in serum of gastric adenocarcinoma patients and its clinical significance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 12
Page:
2255-2259
Research Field:
Publishing date:

Info

Title:
Expression of FABP4 in serum of gastric adenocarcinoma patients and its clinical significance
Author(s):
LIU Li1; 2; DENG Wenhong1; 2
1.Department of Gastrointestinal Surgery;2.Central Laboratory,Renmin Hospital of Wuhan University,Hubei Wuhan 430060,China.
Keywords:
fatty acid binding protein 4 (FABP4); gastric adenocarcinoma; clinicopathology; serum tumor markers; prognosis
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.12.014
Abstract:
Objective:To investigate the expression and clinical significance of fatty acid binding protein 4 (FABP4) in serum of patients with gastric adenocarcinoma.Methods:37 patients with gastric adenocarcinoma diagnosed and treated in our hospital were selected as the study group,and 74 healthy persons were selected as the control group.The expression of FABP4 in serum of the two groups was detected by enzyme-linked immunosorbent assay(ELISA).The relationship between serum FABP4 expression and clinicopathological parameters of patients with gastric adenocarcinoma was analyzed.The role of FABP4 expression in diagnosis and prognosis of gastric adenocarcinoma was analyzed.Results:The relative expression of FABP4 in the serum of patients with gastric adenocarcinoma was significantly lower than that of healthy controls(P<0.05).The expression level of FABP4 was higher in patients with tumor diameter≤3 cm than in patients with tumor diameter>3 cm(P<0.05).The serum FABP4 level was significantly lower in patients with TNM stage III+IV than in patients with stage I+II(P<0.05).The serum FABP4 level was lower in patients with positive lymph node metastasis than in patients with negative lymph node metastasis (P<0.05).The area under the ROC curve (AUC) of FABP4 for the diagnosis of gastric adenocarcinoma was 0.703 (P=0.001),with a sensitivity and specificity of 73.0% and 62.2%,respectively,and a cut-off value of 16.21.The ROC curve of FABP4 for the diagnosis of gastric adenocarcinoma with lymph node metastasis was 0.738(P=0.014),with a sensitivity and specificity of 95.0% and 52.9%,respectively,and a cut-off value of 16.37.Conclusion:FABP4 has a low expression in serum of gastric adenocarcinoma patients,and low expression of FABP4 is closely related to poor prognosis of gastric adenocarcinoma patients,which can be used as a new biomarker and diagnostic target of gastric adenocarcinoma.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ RON I,LERNER RK,RATHAUS M,et al.The adipokine FABP4 is a key regulator of neonatal glucose homeostasis［J］.JCI Insight,2021,6(20):e138288.
［3］ HUA TNM,KIM MK,VO VTA,et al.Inhibition of oncogenic Src induces FABP4-mediated lipolysis via PPARγ activation exerting cancer growth suppression［J］.EBioMedicine,2019,41:134-145.
［4］ GYAMFI J,YEO JH,KWON D,et al.Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer［J］.NPJ Breast Cancer,2021,7(1):129.
［5］ MUKHERJEE A,CHIANG CY,DAIFOTIS HA,et al.Adipocyte-Induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance［J］.Cancer Res,2020,80(8):1748-1761.
［6］ UEHARA H,TAKAHASHI T,OHA M,et al.Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression［J］.Int J Cancer,2014,135(11):2558-2568.
［7］ ZHANG Y,ZHANG W,XIA M,et al.High expression of FABP4 in colorectal cancer and its clinical significance［J］.J Zhejiang Univ Sci B,2021,22(2):136-145.
［8］ ZHONG CQ,ZHANG XP,MA N,et al.FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma［J］.Cancer Med,2018,7(6):2629-2640.
［9］ WANG FH,ZHANG XT,LI YF,et al.The Chinese Society of Clinical Oncology (CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021［J］.Cancer Commun(Lond),2021,41(8):747-795.
［10］ 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2019,41(01):19-28. ZHENG RS,SUN KX,ZHANG SW,et al.Analysis of malignant tumor prevalence in China in 2015［J］.Chinese Journal of Oncology,2019,41(01):19-28.
［11］ 于颖彦,吕有勇.胃癌病理分型和诊断标准的建议［J］.中华病理学杂志,2010,39(04):266-269. YU YY,LV YY.Suggestions for pathological typing and diagnostic criteria of gastric cancer［J］.Chinese Journal of Pathology,2010,39(04):266-269.
［12］ 何裕隆.胃癌病理分型研究进展［J］.中国实用外科杂志,2005,25(07):438-440. HE YL.Progress in the study of pathological staging of gastric cancer［J］.Chinese Journal of Practical Surgery,2005,25(07):438-440.
［13］ HU B,EL HAJJ N,SITTLER S,et al.Gastric cancer:Classification,histology and application of molecular pathology［J］.J Gastrointest Oncol,2012,3(3):251-261.
［14］ MACHLOWSKA J,BAJ J,SITARZ M,et al.Gastric cancer:epidemiology,risk factors,classification,genomic characteristics and treatment strategies［J］.Int J Mol Sci,2020,21(11):4012.
［15］ EDWARDS BR.Lipid biogeochemistry and modern lipidomic techniques［J］.Ann Rev Mar Sci,2023,15:485-508.
［16］ MATSUOKA T,YASHIRO M.Biomarkers of gastric cancer:Current topics and future perspective［J］.World J Gastroenterol,2018,24(26):2818-2832.
［17］ CHEN QY,HUANG XB,ZHAO YJ,et al.The peroxisome proliferator-activated receptor agonist rosiglitazone specifically represses tumour metastatic potential in chromatin inaccessibility-mediated FABP4-deficient gastric cancer［J］.Theranostics,2022,12(4):1904-1920.
［18］ 陈轶霞,骆学农,王红宁.脂肪酸结合蛋白及其生物学功能［J］.生命的化学,2012,32(06):502-506. CHEN YX,LUO XN,WANG HN.Fatty acid binding proteins and their biological functions［J］.Chemistry of Life,2012,32(06):502-506.
［19］ GRUBER N,RATHAUS M,RON I,et al.Fatty acid-binding protein 4:a key regulator of ketoacidosis in new-onset type 1 diabetes［J］.Diabetologia,2022,65(2):366-374.
［20］ 罗新新,徐国良,黎宇,等.葛根调节脂肪细胞糖脂代谢改善胰岛素抵抗的研究［J］.中国中药杂志,2016,41(14):2687-2694. LUO XX,XU GL,LI Y,et al.Study on the regulation of glucolipid metabolism in adipocytes by Pueraria lobata to improve insulin resistance［J］.Chinese Journal of Traditional Chinese Medicine,2016,41(14):2687-2694.
［21］ ZHANG W,ZHANG Y,ZHU Q.Cigarette smoke extract-mediated FABP4 upregulation suppresses viability and induces apoptosis,inflammation and oxidative stress of bronchial epithelial cells by activating p38 MAPK/MK2 signaling pathway［J］.J Inflamm (Lond),2022,19(1):7.
［22］ BERGER E,GELOEN A.FABP4 controls fat mass expandability (adipocyte size and number) through inhibition of CD36/SR-B2 signalling［J］.Int J Mol Sci,2023,24(2)：1032.
［23］ PRENTICE KJ,SAKSI J,HOTAMISLIGIL GS.Adipokine FABP4 integrates energy stores and counterregulatory metabolic responses［J］.J Lipid Res,2019,60(4):734-740.
［24］ 张雨,刘芳.FABP4在肿瘤发生发展的初步研究进展［J］.中国生育健康杂志,2020,31(06):577-579. ZHANG Y,LIU F.Preliminary research progress of FABP4 in tumorigenesis development［J］.Chinese Journal of Reproductive Health,2020,31(06):577-579.
［25］ TSAKOGIANNIS D,KALOGERA E,ZAGOURI F,et al.Determination of FABP4,RBP4 and the MMP-9/NGAL complex in the serum of women with breast cancer［J］.Oncol Lett，2021,21(2):85.
［26］ WU Z,JEONG JH,REN C,et al.Fatty acid-binding protein 4 (FABP4) suppresses proliferation and migration of endometrial cancer cells via PI3K/Akt pathway［J］.Onco Targets Ther，2021,14:3929-3942.
［27］ ZHANG Y,ZHAO X,DENG L,et al.High expression of FABP4 and FABP6 in patients with colorectal cancer［J］.World J Surg Oncol，2019,17(1):171.
［28］ 刘松意,宫月华,邢承忠.FABP家族与胃癌风险、预后的相关性及其功能研究［J］.胃肠病学,2020,25(12):717-723. LIU SY,GONG YH,XING CZ.Correlation of FABP family with gastric cancer risk,prognosis and its function［J］.Gastroenterology,2020,25(12):717-723.

Memo

Memo:
National Natural Science Foundation of China(No.82172855);国家自然科学基金(编号：82172855)；湖北省自然科学基金(编号：2021CFB365)
Last Update: 1900-01-01